BioSpace News Archive

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

MP0317 activates multiple antitumor immune cell types in vitro when in the presence of tumor stroma associated FAP MP0317 mouse surro gate localizes to FAP-expressing tumors and induces strong and durable anti-tumor responses without systemic toxicity, and demonstrates strong anti-tumor immune memory responses ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / September 24, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-bu

Heart failure (HF) is a cardiovascular epidemic. In addition to being increasingly prevalent, HF patients often have poor outcomes after initial diagnosis and poor quality of life. The Ameri

Relationship to enhance patient outcomes, efficiency for healthcare provider servicing the Central Coast of California

Nonprofit consultancy Neurodiversity in the Workplace (NITW), longtime partner of Dell Technologies, SAP and other inclusive employers seeking the talents of autistic people, is expanding its reach after a generous endowment from philanthropist Lisa Yang.

FARE, the world’s leading non-governmental organization engaged in food allergy advocacy and the largest private funder of food allergy research, announced the full schedule for its upcoming 2020 Living Teal™ Global Summit.

Rhizen Pharmaceuticals S.A. today announced the publication of the results from the Phase I/Ib study of Tenalisib (RP6530), the company’s novel next generation dual PI3K δ/γ inhibitor, in the journal Cancers . --- Single-agent Tenalisib was well tolerated with a good overall response rate (ORR) in both peripheral and cutaneous T-cell Lymphoma patients (PTCL and CTCL) The results include safety and efficacy informatio

Spirovant Sciences, a gene therapy company developing treatments and cures for genetic lung diseases including cystic fibrosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug and Rare Pediatric Disease Designations to its lead product candidate, SPIRO-2101, for the treatment of cystic fibrosis.

Miami-based Leon Medical Centers, Inc. announced today that they have been honored with the Healthcare Information and Management Systems Society (HIMSS) Analytics Stage 7 Award, for its continuous efforts to improve patient outcomes through the implementation of EHR technology practices.

Flagship Pioneering today announced the launch of Valo Health, LLC (Valo), a drug discovery technology company setting out to transform how oncology, neurodegenerative, and cardiovascular disease drugs are created, developed, and approved.